{"organizations": [], "uuid": "6d5a4850a378e5eb7a95059c1ca671c6d38378b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eyegate-submits-investigational-de/brief-eyegate-submits-investigational-device-exemption-amendment-for-ocular-bandage-gel-idUSASC0A37Y", "country": "US", "domain_rank": 408, "title": "BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-22T20:45:00.000+03:00", "replies_count": 0, "uuid": "6d5a4850a378e5eb7a95059c1ca671c6d38378b6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eyegate-submits-investigational-de/brief-eyegate-submits-investigational-device-exemption-amendment-for-ocular-bandage-gel-idUSASC0A37Y", "ord_in_thread": 0, "title": "BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eyegate pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) - EyeGate Pharmaceuticals Inc:\n* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL\n* EYEGATE PHARMACEUTICALS INC - RESPONSE TO FOURTH ACTION ITEM EXPECTED IN Q2 OF 2018 WITH POTENTIAL TO START CLINICAL STUDY IN Q3 OF 2018\n* EYEGATE PHARMACEUTICALS INC - WORK CONTINUES ON FILTER VALIDATION REQUIREMENT ASSOCIATED WITH EYEGATE OBG PRODUCT\n* EYEGATE PHARMACEUTICALS - ADDRESSED THREE OF FOUR OUTSTANDING ITEMS IN SECOND AMENDMENT IN RESPONSE TO U.S. FDA’S REVIEW OF FIRST AMENDMENT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T20:45:00.000+03:00", "crawled": "2018-05-23T15:14:44.023+03:00", "highlightTitle": ""}